TG Therapeutics (NKB2) Stock Overview
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
NKB2 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
TG Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$46.90 |
| 52 Week High | US$46.90 |
| 52 Week Low | US$22.47 |
| Beta | 1.68 |
| 1 Month Change | 41.27% |
| 3 Month Change | 70.73% |
| 1 Year Change | 48.68% |
| 3 Year Change | 113.96% |
| 5 Year Change | 44.09% |
| Change since IPO | 1,355.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| NKB2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.3% | 1.0% | -1.5% |
| 1Y | 48.7% | -5.4% | 1.9% |
Return vs Industry: NKB2 exceeded the German Biotechs industry which returned -5.4% over the past year.
Return vs Market: NKB2 exceeded the German Market which returned 1.9% over the past year.
Price Volatility
| NKB2 volatility | |
|---|---|
| NKB2 Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 8.5% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: NKB2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: NKB2's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 399 | Mike Weiss | www.tgtherapeutics.com |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
TG Therapeutics, Inc. Fundamentals Summary
| NKB2 fundamental statistics | |
|---|---|
| Market cap | €6.68b |
| Earnings (TTM) | €406.24m |
| Revenue (TTM) | €615.96m |
Is NKB2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NKB2 income statement (TTM) | |
|---|---|
| Revenue | US$700.35m |
| Cost of Revenue | US$118.68m |
| Gross Profit | US$581.67m |
| Other Expenses | US$119.77m |
| Earnings | US$461.90m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.26 |
| Gross Margin | 83.05% |
| Net Profit Margin | 65.95% |
| Debt/Equity Ratio | 127.8% |
How did NKB2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/25 03:04 |
| End of Day Share Price | 2026/06/25 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TG Therapeutics, Inc. is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| William Wood | B. Riley Securities, Inc. |
| Mayank Mamtani | B. Riley Securities, Inc. |